Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Must have received: cytotoxic chemotherapy — upfront initial therapy

Disease that has progressed on or relapsed after upfront initial therapy, which must have included traditional chemotherapy

Cannot have received: cabozantinib (cabozantinib)

Exception: prior therapy with cabozantinib without progression/relapse and prior use of other multi-tyrosine kinase inhibitors is allowed

Prior progression/relapse with cabozantinib. Prior therapy with cabozantinib without progression/relapse and prior use of other multi-tyrosine kinase inhibitors is allowed.

Cannot have received: high-dose ifosfamide (ifosfamide)

Prior therapy with high-dose ifosfamide (> 10 g/m2/cycle) at any point.

Cannot have received: small molecule inhibitor

Any small molecule inhibitor therapy within 5 half-lives of the drug or 14 days, whichever is shorter, before enrollment.

Cannot have received: myelosuppressive chemotherapy

Myelosuppressive chemotherapy within 14 days before enrollment.

Cannot have received: autologous bone marrow transplant

Autologous bone marrow transplant (auto-BMT) within 42 days before enrollment.

Cannot have received: immunotherapy (CAR-T cell therapy)

Immunotherapy, including chimeric antigen receptor T-cells (CAR-T), within 21 days before enrollment.

Cannot have received: radiation therapy

Small port radiation therapy within 14 days before enrollment. Substantial bone marrow radiation (i.e. > 50% of the pelvis) or craniospinal radiation within 4 weeks before enrollment.

Cannot have received: major surgery

Major surgery (i.e. abdominal surgery; excluding intracranial surgery as noted above) within 14 days before enrollment. Minor surgeries (including mediport or tunneled catheter placement; excluding needle biopsy for tumor sampling or peripherally inserted central catheter placement) within 10 days before enrollment.

Cannot have received: hematopoietic growth factor

Hematopoietic growth factors within 7 days (for short-acting growth factor) or 14 days (for long-acting growth factor) before enrollment.